Form 8-K Orexigen Therapeutics, For: Aug 07

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Form 8-K Orexigen Therapeutics, For: Aug 07

Orexigen Therapeutics, Inc. (OREX) Reports In-Line Q2 Loss of 21c/Share

August 7, 2014 7:23 AM EDT

Orexigen Therapeutics, Inc. (NASDAQ: OREX) reported Q2 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $857 thousand versus the consensus estimate of $1 million.

NB32 program update:

NB32 (32 mg naltrexone sustained-release (SR)/360 mg bupropion SR), an investigational medicine for weight loss... More